Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

E. Dadachova; B. Bouzahzah; L. S. Zuckier; R. G. Pestell

doi:10.1016/S0969-8051(01)00279-7

Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

E. Dadachova, B. Bouzahzah, L. S. Zuckier, R. G. Pestell

Research output: Contribution to journal › Article › peer-review

89 Citations (Scopus)

Abstract

The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal ¹⁸⁸Re in the form of ¹⁸⁸Re-perrhenate was therefore compared with ¹³¹I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, ¹⁸⁸Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that ¹⁸⁸Re-perrhenate is able to deliver a dose 4.5 times higher than ¹³¹I suggesting it may provide enhanced therapeutic efficacy.

Original language	English
Pages (from-to)	13-18
Number of pages	6
Journal	Nuclear Medicine and Biology
Volume	29
Issue number	1
DOIs	https://doi.org/10.1016/S0969-8051(01)00279-7
Publication status	Published - 2002
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0969-8051(01)00279-7

Cite this

@article{d64f1cf888c64b3c89d729337480404f,

title = "Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)",

abstract = "The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal 188Re in the form of 188Re-perrhenate was therefore compared with 131I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, 188Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that 188Re-perrhenate is able to deliver a dose 4.5 times higher than 131I suggesting it may provide enhanced therapeutic efficacy.",

keywords = "Iodine, Rhenium, Iodide symporter (NIS), Mammary tumor, Radiation dose, Sodium, Therapy",

author = "E. Dadachova and B. Bouzahzah and Zuckier, {L. S.} and Pestell, {R. G.}",

note = "Funding Information: This work was supported by AECOM grant 95269593 (to E.D.) and R01CA70897, R01CA75503, R01CA77552, the Komen Foundation, Breast Cancer Alliance, Inc., and Cancer Center Core National Institutes of Health grant 5-P30-CA13330–26 (to R.G.P.). The authors would like to thank Prof. N.Carrasco, Albert Einstein College of Medicine, for insightful comments. ",

year = "2002",

doi = "10.1016/S0969-8051(01)00279-7",

language = "English",

volume = "29",

pages = "13--18",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

AU - Dadachova, E.

AU - Bouzahzah, B.

AU - Zuckier, L. S.

AU - Pestell, R. G.

N1 - Funding Information: This work was supported by AECOM grant 95269593 (to E.D.) and R01CA70897, R01CA75503, R01CA77552, the Komen Foundation, Breast Cancer Alliance, Inc., and Cancer Center Core National Institutes of Health grant 5-P30-CA13330–26 (to R.G.P.). The authors would like to thank Prof. N.Carrasco, Albert Einstein College of Medicine, for insightful comments.

PY - 2002

Y1 - 2002

N2 - The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal 188Re in the form of 188Re-perrhenate was therefore compared with 131I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, 188Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that 188Re-perrhenate is able to deliver a dose 4.5 times higher than 131I suggesting it may provide enhanced therapeutic efficacy.

AB - The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal 188Re in the form of 188Re-perrhenate was therefore compared with 131I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, 188Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that 188Re-perrhenate is able to deliver a dose 4.5 times higher than 131I suggesting it may provide enhanced therapeutic efficacy.

KW - Iodine

KW - Rhenium

KW - Iodide symporter (NIS)

KW - Mammary tumor

KW - Radiation dose

KW - Sodium

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036153579&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(01)00279-7

DO - 10.1016/S0969-8051(01)00279-7

M3 - Article

C2 - 11786271

AN - SCOPUS:0036153579

SN - 0969-8051

VL - 29

SP - 13

EP - 18

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 1

ER -

Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this